The United States Court of Appeals for the Eleventh Circuit recently upheld the convictions of Steven Chun and Daniel Tondre for their roles in a bribery scheme involving the prescription of Subsys, a fentanyl-based medication. The court's decision, filed on August 18, 2026, impacts the healthcare and pharmaceutical industries, highlighting the legal consequences of violating anti-kickback laws.
Chun, a physician specializing in pain management, and Tondre, a sales representative for Insys Therapeutics, were found guilty of conspiring to violate the Anti-Kickback Statute. This statute prohibits the exchange of kickbacks in connection with federal healthcare programs. The case underscores the ongoing issues of corruption in the pharmaceutical industry and the importance of adhering to ethical practices in prescribing medications.
Background
The case stems from a broader investigation into Insys Therapeutics, which was previously implicated in a bribery scandal involving the promotion of Subsys, a powerful opioid. In a related case, United States v. Simon, the First Circuit affirmed the convictions of several Insys executives for conspiring to bribe physicians to prescribe Subsys. The Eleventh Circuit's ruling in Chun's case builds on the findings from Simon, revealing a pattern of illegal activity within the company.
On March 12, 2020, a grand jury in the Middle District of Florida indicted Chun and Tondre, charging them with multiple offenses related to the bribery scheme. The indictment alleged that from August 2012 to July 2015, they conspired to solicit and receive bribes in exchange for prescribing Subsys. The case was tried in May 2022, where the jury found both defendants guilty on several counts, including conspiracy to violate the Anti-Kickback Statute.
The Ruling
The Eleventh Circuit, composed of Judges Newsom, Brasher, and Tjoflat, affirmed the lower court's decision, rejecting the defendants' appeals. The court ruled that there was sufficient evidence to support the jury's verdicts, stating, "The evidence that Chun had the specific intent to do something the law forbids was overwhelming." The judges emphasized that the defendants knowingly participated in a scheme that violated federal law.
The court's opinion highlighted the importance of the Anti-Kickback Statute in maintaining the integrity of healthcare practices. It noted that Chun and Tondre's actions were not only illegal but also detrimental to patient care, as they prioritized financial gain over the well-being of their patients.
Impact
This ruling has significant implications for the healthcare industry, particularly in the context of opioid prescriptions. It reinforces the legal framework surrounding anti-kickback laws and serves as a warning to healthcare professionals and pharmaceutical companies about the consequences of engaging in corrupt practices. The decision may deter similar conduct in the future, as it sets a precedent for holding individuals accountable for their roles in bribery schemes.
The court's affirmation of Chun and Tondre's convictions also underscores the importance of transparency and ethical behavior in the medical field. As the opioid crisis continues to affect communities across the country, this ruling emphasizes the need for strict adherence to legal and ethical standards in prescribing practices.
What's Next
Following the Eleventh Circuit's ruling, Chun and Tondre may seek further legal recourse, potentially pursuing an appeal to the Supreme Court. However, details regarding any related cases or future legal actions were not available in the court filing. The outcome of this case could influence ongoing discussions about healthcare regulations and the accountability of pharmaceutical companies.